BAY73-4506 Probe Substrate Study

NCT01287598 | Completed Phase 1 FDA Drug

• 1 other identifier: 12434
• Study Type: interventional
• Target: 41
• Locations: 1 country
• Sites: 4

Brief Summary

• To evaluate the effect of BAY73-4506 on the pharmacokinetics of probe substrates of CYP 2C9 (warfarin), 2C19 (omeprazole) and 3A4 (midazolam) administered in a cocktail approach and on the pharmacokinetics of a probe substrate of CYP 2C8 (rosiglitazone)
• To evaluate safety, anti-tumor activity, pharmacokinetics, and pharmacodynamics of BAY73-4506 in patients with advanced solid tumors

Conditions

Neoplasms

Keywords

Phase I; Probe substrate; target therapy; small molecule; pharmacokinetics

Outcome Measures

Primary Outcomes (1)

• Pharmacokinetics of probe substrates (AUC, Cmax, etc.)

  Approximately 6 weeks

Secondary Outcomes (2)

• Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

  Up to 3 years or longer if indicated

• Adverse event collection

  Up to 3 years or longer if indicated

Study Arms (2)

Arm 1

EXPERIMENTAL

Regorafenib (Stivarga, BAY73-4506) + warfarin + omeprazole + midazolam

Drug: Regorafenib (Stivarga, BAY73-4506); Drug: Warfarin; Drug: Omeprazole; Drug: Midazolam

Arm 2

EXPERIMENTAL

Regorafenib (Stivarga, BAY73-4506) + rosiglitazone

Drug: Regorafenib (Stivarga, BAY73-4506); Drug: Rosiglitazone

Interventions

Regorafenib (Stivarga, BAY73-4506) DRUG

BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule

Arm 1; Arm 2

Warfarin DRUG

CYP 2C9 (warfarin) at Cycle 1

Arm 1

Omeprazole DRUG

CYP 2C19 (omeprazole) at Cycle 1

Arm 1

Midazolam DRUG

CYP 3A4 (midazolam) at Cycle 1

Arm 1

Rosiglitazone DRUG

CYP2C8 (rosiglitazone) at Cycle 1

Arm 2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female and male subjects must be ≥ 18 years at the first screening examination / visit
• ECOG Performance Status of ≤ 2
• Histological or cytological documentation of confirmed advanced solid tumors. Subjects should have measurable or non-measurable disease according to RECIST
• Life Expectancy of at least 3 months
• Adequate bone marrow, liver, and renal functions as assessed by the following laboratory requirements conducted within 14 days prior to the first study treatment:
• Hemoglobin ≥ 9.0 g/dL
• Absolute neutrophil count (ANC) ≥1,500/mm3
• Platelet count ≥ 100,000/ mm3
• Total bilirubin ≤ 1.5 times the upper limit of normal (ULN)
• Alkaline phosphatase ≤ 2 times ULN
• ALT and AST ≤ 2.5 x ULN (≤ 5.0 x ULN for subjects with cancer involving the liver)
• Serum creatinine ≤ 1.5 times ULN and glomerular filtration rate (GFR)≥ 30 ml/min/1.73 m2, according to the MDRD (Modified Diet in Renal Disease) abbreviated formula
• Lipase ≤ 1.5 ULN
• INR and PTT ≤ 1.5 ULN
• Subjects who are therapeutically treated with warfarin, heparin or other anticoagulants are not eligible for study participation in Group A. Subjects who are therapeutically treated with warfarin, heparin or other anticoagulants, will be allowed to participate in Group B of the study provided they meet all eligibility criteria. Close monitoring of at least weekly evaluations will be performed until INR or PTT are stable by the local standard of care.

You may not qualify if:

• Negative serum pregnancy test must be obtained within 7 days prior to the start of treatment in women of childbearing potential. Negative results must be available prior to study treatment.
• Subjects enrolled in this study must use adequate barrier birth control measures prior to, during the course of the study, and 3 months after the last administration of regorafenib.
• An adequate contraception includes the use of condoms or a vasectomy, hormonal contraception with implants or combined PO contraceptives, certain intrauterine devices, bilateral tubal ligation, or hysterectomy. In addition, adequate birth control measures for the subject's partner is required, such as a hormonal contraception with implants or combined PO contraceptives, certain intrauterine devices, bilateral tubal ligation, or hysterectomy, use of condoms or a vasectomy.
• History of cardiac disease: Congestive heart failure (New York Heart Association, NYHA, Class III or IV) or active coronary artery disease (unstable angina \[angina symptoms at rest\] or new-onset angina \[began within the last 3 months\] or myocardial infarction within the past 6 months). Treatment with Type 1A or 3 anti-arrhythmics, such as Quinidine, Procainamide, Amiodarone, or Sotalol are not permitted. β-Blockers and digoxin are permitted.
• Left ventricular ejection fraction (LVEF) \< 50% or below the LLN for the institution (whichever is higher).
• Subjects with pheochromocytoma
• Dehydration NCI-CTCAE, version 4, Grade \> 1
• Uncontrolled hypertension (failure of diastolic blood pressure to fall to or below 90 mmHg or systolic blood pressure to fall to or below 140 mmHg with or without the use of antihypertensive drugs). At screening, subjects with history of hypertension should be on a stable anti-hypertensive treatment for at least 7 days prior to the first dose of study drug.
• Patients with known allergy to any of the study drug(s) to be administered, including known severe allergies, non-allergic drug reactions, or multiple drug allergies to any of the study drug(s) to be administered. This is also includes hypersensitivity to any of the compounds or excipients that will be administered to the study subject, specifically regorafenib, and warfarin, omeprazole and midazolam for subjects in Group A, or rosiglitazone for subjects in Group B.
• Subjects with arterial or venous thrombotic or embolic events, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, or pulmonary embolism within 6 months before the start of study medication.

Sponsors & Collaborators

• Bayer: lead

Study Sites (4)

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

Location

British Columbia Cancer Agency-Vancouver Centre

Vancouver, British Columbia, V5Z 4E6, Canada

Location

Juravinski Cancer Centre

Hamilton, Ontario, L8V 5C2, Canada

Location

Sir Mortimer B. Davis Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada

Location

Related Links

• Click here to find results for studies related to Bayer Healthcare products.

MeSH Terms

Conditions

Neoplasms

Interventions

regorafenib; Warfarin; Omeprazole; Midazolam; Rosiglitazone

Intervention Hierarchy (Ancestors)

4-Hydroxycoumarins; Coumarins; Benzopyrans; Pyrans; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; 2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Benzimidazoles; Benzodiazepines; Benzazepines; Thiazolidinediones; Thiazoles; Azoles

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 31, 2011
• First Posted: February 1, 2011
• Study Start: August 2, 2011
• Primary Completion: July 3, 2018
• Study Completion: July 30, 2018
• Last Updated: July 10, 2019

Record last verified: 2019-07

Locations

CA (4)